Literature DB >> 9169894

Thrombolytic therapy for eligible elderly patients with acute myocardial infarction.

H M Krumholz1, J E Murillo, J Chen, V Vaccarino, M J Radford, E F Ellerbeck, Y Wang.   

Abstract

OBJECTIVE: To determine the correlates of thrombolytic therapy use in a population-based sample of elderly patients hospitalized with acute myocardial infarction who were eligible for the therapy on presentation.
DESIGN: Retrospective cohort study using data from medical charts and administrative files.
SETTING: All acute care, nongovernmental hospitals in Connecticut. PATIENTS: A cohort of 3093 patients aged 65 years and older with a discharge diagnosis of acute myocardial infarction covered by Medicare from May 1992 to May 1993.
RESULTS: Among the 753 patients with ST-segment elevation of 1 mm or more in at least 2 contiguous leads, left bundle branch block not known to be old, and no absolute contraindications to thrombolytic therapy who were not referred for direct angioplasty or bypass surgery, 419 patients (56%) did not receive thrombolytic therapy. The strongest predictors of not receiving thrombolytic therapy included advanced age, absence of chest pain, presentation more than 6 hours after the onset of symptoms, left bundle branch block, total ST-segment elevation of 6 mm or less, presence of Q waves, ST-segment elevation in only 2 leads, and altered mental status. Physicians documented why they did not administer thrombolytic therapy in 19% of the charts. Delay in presentation and increased age were the most common reasons cited. Among the subset of 261 patients who presented with chest pain and within 6 hours of symptoms, 197 (75%) received thrombolytic therapy.
CONCLUSIONS: Many eligible and ideal patients for thrombolytic therapy are not treated. Physicians are less likely to use thrombolytic therapy in eligible patients with characteristics associated with an increased risk of bleeding, lower-risk infarction, less certain diagnosis, less certain efficacy, or altered mental status. These findings suggest that the lack of treatment represents a clinical judgment rather than an inadvertent omission. In some cases, such as the lower use of thrombolytic therapy with older age, these judgments are not consistent with the published literature and may represent opportunities to improve care.

Entities:  

Mesh:

Year:  1997        PMID: 9169894

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  20 in total

Review 1.  Thrombolytic therapy in acute myocardial infarction.

Authors:  U Priglinger; K Huber
Journal:  Drugs Aging       Date:  2000-04       Impact factor: 3.923

Review 2.  The aging heart and post-infarction left ventricular remodeling.

Authors:  Henry Shih; Brian Lee; Randall J Lee; Andrew J Boyle
Journal:  J Am Coll Cardiol       Date:  2011-01-04       Impact factor: 24.094

3.  Acute reperfusion therapy in ST-elevation myocardial infarction from 1994-2003.

Authors:  Brahmajee K Nallamothu; Martha E Blaney; Susan M Morris; Lori Parsons; Dave P Miller; John G Canto; Hal V Barron; Harlan M Krumholz
Journal:  Am J Med       Date:  2007-08       Impact factor: 4.965

4.  Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods.

Authors:  Thérèse A Stukel; Elliott S Fisher; David E Wennberg; David A Alter; Daniel J Gottlieb; Marian J Vermeulen
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

5.  Effect of abnormal fasting plasma glucose level on all-cause mortality in older patients with acute myocardial infarction: results from the Beijing Elderly Acute Myocardial Infarction Study (BEAMIS).

Authors:  Shi-Wei Yang; Yu-Jie Zhou; Xiao-Min Nie; Yu-Yang Liu; Jie Du; Da-Yi Hu; De-An Jia; Fei Gao; Bin Hu; Zhe Fang; Hong-Ya Han; Xiao-Li Liu; Zhen-Xian Yan; Jian-Long Wang; Qi Hua; Yu-Jie Shi; Hong-Wei Li
Journal:  Mayo Clin Proc       Date:  2011-02       Impact factor: 7.616

6.  Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials).

Authors:  Shaheeda Ahmed; Elliott M Antman; Sabina A Murphy; Robert P Giugliano; Christopher P Cannon; Harvey White; David A Morrow; Eugene Braunwald
Journal:  J Thromb Thrombolysis       Date:  2006-04       Impact factor: 2.300

7.  Long-term outcomes of regional variations in intensity of invasive vs medical management of Medicare Patients with acute myocardial infarction.

Authors:  Therese A Stukel; F Lee Lucas; David E Wennberg
Journal:  JAMA       Date:  2005-03-16       Impact factor: 56.272

8.  Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective.

Authors:  Frederick A Spencer; Gilles Montalescot; Keith A A Fox; Shaun G Goodman; Christopher B Granger; Robert J Goldberg; Gustavo B F Oliveira; Frederick A Anderson; Kim A Eagle; Gordon Fitzgerald; Joel M Gore
Journal:  Eur Heart J       Date:  2010-03-15       Impact factor: 29.983

Review 9.  Utilisation of thrombolytic therapy in older patients with myocardial infarction.

Authors:  K L Woods; D Ketley
Journal:  Drugs Aging       Date:  1998-12       Impact factor: 3.923

10.  Clinical prognosis, pre-existing conditions and the use of reperfusion therapy for patients with ST segment elevation acute myocardial infarction.

Authors:  Andrea B Parker; C David Naylor; Alice Chong; David A Alter
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.